340B Omnibus Guidance Could Lead To Increased Drug Costs

Law360, New York (September 3, 2015, 11:35 AM ET) -- New guidance from the U.S. Health Resources Services Administration clarifying certain definitions integral to the 340B Drug Pricing Program will significantly limit the number of patients eligible to receive 340B drugs, resulting in substantial increases in prescription drug costs for many 340B-participating health care providers.[1] The guidance contains a six-part test for an “eligible patient,” substantially more onerous to meet than HRSA’s previous three-part test and directly conflicting with previous guidance issued by HRSA. If this new “patient” definition is finalized, we expect that many 340B covered...

To view the full article, register now.